The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
 
Richard T. Penson
Honoraria - Abbvie; AstraZeneca; Clovis Oncology; Eisai; Genentech/Roche; Janssen Oncology; Mersana; Newlink Genetics; Sutro Biopharma; Tesaro; Vascular Biogenics
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Baxalta; Care4ward; Clovis Oncology; Eisai; Genentech; Janssen Oncology; Merck; Mersana; Sutro Biopharma; Tesaro; Vascular Biogenics
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Cerulean Pharma (Inst); Eisai (Inst); Genentech (Inst); Regeneron (Inst); Sanofi (Inst); Tesaro (Inst); Vascular Biogenics (Inst)
Patents, Royalties, Other Intellectual Property - Blackwell Publishing; BMJ; UpToDate
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Genentech; Tesaro; Vascular Biogenics
Other Relationship - Abbvie; AstraZeneca
 
Rebecca Christian Arend
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Clovis Oncology; GlaxoSmithKline; Leap Therapeutics; VBL Therapeutics
Travel, Accommodations, Expenses - Caris Life Sciences; GlaxoSmithKline; VBL Therapeutics
 
Angeles Alvarez Secord
Honoraria - Myriad Genetics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immutep (Inst); Merck (Inst); OncoQuest Pharmaceuticals (Inst); PharmaMar (Inst); Seagen (Inst); Tesaro (Inst); VBL Therapeutics (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Aravive; GOG Foundation; OncoQuest Pharmaceuticals; Regeneron; Roche/Genentech; VBL Therapeutics
 
Antonio Casado Herraez
Consulting or Advisory Role - Eisai; Eisai; Merck Sharp & Dohme; PharmaMar; Roche
Research Funding - Pharmamar (Inst)
Travel, Accommodations, Expenses - Lilly; Pharmamar; Roche
Other Relationship - Lilly (Inst)
 
Thomas J. Herzog
Leadership - GOG Partners
Consulting or Advisory Role - Aravive; AstraZeneca; Caris MPI; Clovis Oncology; Eisai; Epsilogen; GlaxoSmithKline; Johnson & Johnson; Merck; Roche/Genentech
 
Jonathan A. Ledermann
Consulting or Advisory Role - Amgen; Artios; AstraZeneca/MedImmune; Clovis Oncology; Eisai; GlaxoSmithKline UK Ltd.; Merck; Tesaro; VBL Therapeutics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Pfizer; Tesaro/GSK
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst)
Other Relationship - Regeneron
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - Alkermes (Inst); Aravive; AstraZeneca; Blueprint Medicines (Inst); Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); I-Mab (Inst); Immunogen; InxMed (Inst); Merck; Mereo BioPharma; Mereo BioPharma (Inst); Mersana (Inst); Myriad Genetics; Novartis; Onconova Therapeutics; OncXerna Therapeutics; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bayer (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Forty Seven (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - GOG Partners (Inst)
 
Ronnie Shapira-Frommer
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Medison; Merck Sharp & Dohme; NeoPharm; Novartis; Roche; Sanofi
Consulting or Advisory Role - Merck Sharp & Dohme; VBL Therapeutics
Research Funding - Merck Sharp & Dohme
 
Krishnansu Sujata Tewari
Honoraria - AstraZeneca; Clovis Oncology; Eisai; Genmab; Merck; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Genmab; Merck; Roche/Genentech; Tesaro
Research Funding - Abbvie (Inst); Genentech/Roche (Inst); Merck (Inst); Morphotek (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Tamar Rachmilewitz Minei
Employment - VBL Therapeutics
Leadership - VBL Therapeutics
Stock and Other Ownership Interests - VBL Therapeutics
Patents, Royalties, Other Intellectual Property - VBL Therapeutics
 
Dror Harats
Employment - VBL Therapeutics
Leadership - VBL Therapeutics
Stock and Other Ownership Interests - VBL Therapeutics
Patents, Royalties, Other Intellectual Property - VBL Therapeutics
 
Shifra Fain Shmueli
Employment - VBL Therapeutics
Stock and Other Ownership Interests - VBL Therapeutics
Patents, Royalties, Other Intellectual Property - VBL Therapeutics
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)